A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
Phase 2
Recruiting
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06630091
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06629584
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT06617858
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06619522
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
Phase 1
Recruiting
- Conditions
- Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06616636
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Closed Loop Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy, a Pilot Study.
Not Applicable
Not yet recruiting
- Conditions
- Peripheral Neuropathy Due to Chemotherapy
- Interventions
- Device: Spinal cord stimulator implant
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT06616649
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Phase 2
Recruiting
- Conditions
- Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06597734
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)
Not yet recruiting
- Conditions
- Orodental Injury
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 300
- Registration Number
- NCT06586892
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Select Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 141
- Registration Number
- NCT06598371
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
Phase 3
Recruiting
- Conditions
- Pancreas CancerOligometastatic
- Interventions
- Radiation: Consolidative Radiation
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT06593431
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath